All In Biotech

NDA 206947 · Eisai INC

Lenvima

Lenvatinib Mesylate · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Feb 13, 2015

Approved uses

12

Original approval plus efficacy supplements

Registered trials

591

73 Phase 3, 146 recruiting

FAERS reports

33,515

29,421 serious, 4,564 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with...

Mechanism: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRA), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 24, 2026 Supplement 35 · Efficacy OrphanLetterLabel
  • Jan 29, 2025 Supplement 33 · Efficacy · priority review OrphanLabelLetter
  • Jun 7, 2024 Supplement 31 · Efficacy OrphanLabelLetter
  • Apr 3, 2024 Supplement 30 · Efficacy · priority review OrphanLabelLetter
  • Oct 23, 2023 Supplement 28 · Efficacy OrphanLetterLabel
  • Dec 19, 2021 Supplement 21 · Efficacy LetterLabel
  • Aug 10, 2021 Supplement 19 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Jul 21, 2021 Supplement 20 · Efficacy · priority review LabelLetter
  • Sep 17, 2019 Supplement 11 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Aug 15, 2018 Supplement 7 · Efficacy OrphanLabelLetter
  • May 13, 2016 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Feb 13, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLabelSummary Review
2 products under this application
  • LENVIMA · LENVATINIB MESYLATE EQ 4MG BASE · CAPSULE, ORAL · Prescription
  • LENVIMA · LENVATINIB MESYLATE EQ 10MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lenvatinib" as an intervention, any sponsor and status, largest first.

All 591 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea4,243
  • hypertension3,829
  • fatigue3,425
  • decreased appetite3,169
  • malignant neoplasm progression2,570
  • nausea2,531
  • blood pressure increased2,189
  • vomiting2,044
  • asthenia1,661
  • dehydration1,548
  • weight decreased1,474
  • malaise1,358

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20132
20144
2015377
2016752
20171,055
20182,284
20192,998
20202,860
20212,880
20224,244
20235,451
20243,810
20253,982
20262,815

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lenvima (Lenvatinib Mesylate)

2024 spending

$876M

Beneficiaries

8,450

37,139 claims

Per beneficiary

$103,626

$491.21 per unit

View as table
YearSpending
2020$367,767,779
2021$452,132,406
2022$625,976,421
2023$778,834,824
2024$875,642,919

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 386 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.